HERSH DINESH PATEL MD., FALSE UNO-FALSE OMNIBUS “WHEN A GOVERNMENT WITNESS LIES THEY MUST LOSE THEIR MEDICAL LICENSE: A COMPLAINT BEFORE DELAWARE MEDICAL BOARD

REPORTED BY

NORMAN J CLEMENT RPH., D.D.S., NORMAN L.CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC.T. SPIRIT OF REV. C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., MBA., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., WALTER F. WRENN III., MD., JULIE KILLINGWORTH, LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, WILLIE GUINYARD BS., JOSEPH WEBSTER MD., M.B.A., BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., RICHARD KAUL, MD., LEROY BAYLOR, JAY K. JOSHI MD., M.B.A., ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS

DONATE LEGAL DEFENSE

OR SEND

$150 DOLLARS TO CASH APP:$docnorm

So, Donate to the “Pharmacist For Healthcare Legal Defense Fund,

WE ARE HEALTHCARE PROVIDERS, NOT STREET DRUG DEALERS “

WE ARE NOT POWERLESS, AND THROUGH OUR VIDEOS, WRITINGS, AND PHOTOGRAPHS WE WILL EXPOSE THE ABUSES AND TYRANNY JUST AS THE VIDEO WAS RECORDED BY THE CELL PHONE CAMERA OF YOUNG DARNELLA FRAZIER, BORE WITNESS TO THE MURDER OF GEORGE FLOYD THE BLOG youarewithinthenorms.com BARES WITNESS AND BOTH ALLOWS THE SYSTEM TO BE HELD ACCOUNTABLE”

HERSH DINESH PATEL MD, ADMITTED CRIMINAL WRONGING DURING CROSS-EXAMINATION AS GOVERNMENT WITNESS IN THE DETROIT-5 TRIAL

HERSH DINESH PATEL MD

HERSH PATEL CROSSED BY DEFENSE ATTY LAURENCE MARGOLIS

Dr. Hersh Dinesh Patel, admitted in District Judge Stephen J. Murphy, III Court today and yesterday (6/6/2022 and 6/7/2022) in UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN SOUTHERN DIVISION in the criminal trial Crim. No. 2:18-cr-20800 that he prescribed unnecessary controlled substance medications to patients and that he intentionally and knowingly performed unnecessary interventional procedures upon patients without medical necessity. I will be forwarding this information to the Delaware Medical License Board.

Jun 6, 2022

NEW DATA ON OPIOID REDUCTIONS

| Clinical Pharmacy and Pharmacology | JAMA Network Open | JAMA Network

Richard Lawhern PHD, writes:

“This June 13, 2022 paper from Stefan G. Kertesz, MD, and Allyson L. Varley, Ph.D. is remarkable for multiple reasons. The paper reviews evidence recently published by others, that involuntary opioid dose restrictions and tapers not only do NOT promote safety for chronic pain patients but are arguably never justified without patient participation and careful monitoring to ensure that the patient is properly managed if tapering fails to produce a useful result. “

What I find perhaps most remarkable about this paper is that the Journal of the AMA published it at all.  At least in my reading, JAMA has pursued a persistently anti-opioid editorial policy, despite the public positions of the AMA Board and CEO to the effect that the 2016 CDC guidelines on the prescription of opioids have arbitrarily and needlessly harmed many patients and their doctors. 
Thus, I must regard the publication of this paper by JAMA to progress in changing the public conversation on these issues.

Feel free to share.  This note will also be posted to multiple social media platforms. 

BILL MURRAY

DISCLAIMER

NOTE: RICHARD LAWHERN PH.D. IS NOT A PART OF NOR A PARTICIPANT IN THE COMPLAINT AGAINST PHYSICIAN HERSH PATEL MD. LAWHERN’S WORK APPEARS IN THIS ARTICLE AS IT IS TIMELY AND HIGHLIGHTS MEDICAL SCIENTIFIC FACTS OVER PROSECUTORIAL COERCION

New Data on Opioid Dose Reduction—Implications for Patient Safety

From the paper:

“Reductions and stoppages in these patients’ prescription regimens are likely to reflect varied motivations and understandings among physicians and other professionals who care for them. Some may reduce doses out of a belief that the dose reductions confer safety and well-being, a perspective reinforced by studies in which voluntary tapers are achievable or even salutary for some patients. However, it is likely that many clinicians are reacting to a fraught public discourse and to external pressures as well, including measures that rate the quality of their work. According to a metric issued by the National Committee for Quality Assurance and taken up by most payers, patients taking a daily dose more than the equivalent of 90 mg of morphine count as receiving poor care, regardless of their prior dose history.2 Such measures do incentivize either reduction or termination of the care relationship. Unsurprisingly, dose reductions and stoppage have become more common in recent years.3


And later in the paper:

“How should clinicians and health systems respond today, in light of these evolving, cautionary findings on opioid dose reduction? Our view is that opioid dose reduction is likely to offer benefits for some while harming others. The harms may include worsening pain, distress, or death. Given this uncertain balance of harm and benefit, it would be wise for health systems to stop promoting this change in care. A policy of tapering all patients to doses lower than a specified threshold cannot be supported by the available evidence. Quality metrics that incentivize these policies, such as the High Dose Opioid criterion promulgated by the National Committee for Quality Assurance,2 are overdue for retirement. Indeed, experts who assisted the Centers for Disease Control and Prevention’s 2016 guideline urged that it not be adopted in the first place.16

RICHARD “RED” LAWHERN

Richard A “Red” Lawhern PhD

Patient Advocate

Twitter: @Lawhern1

Facebook:  https://www.facebook.com/red.lawhern

My Publications: http://www.face-facts.org/Lawhern
Personal Website:  http://www.lawhern.org

FOR NOW, YOU ARE WITHIN

YOUAREWITHINTHENORMS.COM, BENJAMIN CLEMENTINE “THE NEMESIS” LONDON ENGLAN 2015

THE NORMS

DONATE LEGAL DEFENSE

OR SEND

$150 DOLLARS TO CASH APP:$docnorm

So, Donate to the “Pharmacist For Healthcare Legal Defense Fund,

reference:

Leave a Reply